TD Cowen Downgrades Alpine Immune Sciences to Hold
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Boris Peaker downgraded Alpine Immune Sciences (NASDAQ:ALPN) from Buy to Hold, indicating a more cautious outlook on the company's stock.
April 16, 2024 | 10:49 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Alpine Immune Sciences was downgraded by TD Cowen from Buy to Hold, suggesting a neutral outlook on the stock's short-term performance.
The downgrade by a prominent analyst like Boris Peaker from TD Cowen can influence investor sentiment and potentially lead to a more cautious approach towards ALPN stock in the short term. However, the change to a Hold rating suggests a neutral outlook rather than a negative one, hence the score of 0.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100